These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32619641)

  • 1. Specific gyrA Gene Mutations Correlate with High Prevalence of Discordant Levofloxacin Resistance in Mycobacterium tuberculosis Isolates from Beijing, China.
    Huo F; Ma Y; Li S; Xue Y; Shang Y; Dong L; Li Y; Pang Y
    J Mol Diagn; 2020 Sep; 22(9):1199-1204. PubMed ID: 32619641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased prevalence of levofloxacin-resistant Mycobacterium tuberculosis in China is associated with specific mutations within the gyrA gene.
    Huo F; Zhang F; Xue Y; Shang Y; Liang Q; Ma Y; Li Y; Zhao L; Pang Y
    Int J Infect Dis; 2020 Mar; 92():241-246. PubMed ID: 31978580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro susceptibility of a novel fluoroquinolone antibiotic candidate WFQ-228, levofloxacin, and moxifloxacin against Mycobacterium tuberculosis.
    Qiao M; Ren W; Guo H; Huo F; Shang Y; Wang Y; Gao M; Pang Y
    Int J Infect Dis; 2021 May; 106():295-299. PubMed ID: 33864922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of MICs of levofloxacin for Mycobacterium tuberculosis with gyrA mutations.
    Kambli P; Ajbani K; Nikam C; Khillari A; Shetty A; Udwadia Z; Georghiou SB; Rodwell TC; Catanzaro A; Rodrigues C
    Int J Tuberc Lung Dis; 2015 Oct; 19(10):1227-9. PubMed ID: 26459538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.
    Yu X; Wang G; Chen S; Wei G; Shang Y; Dong L; Schön T; Moradigaravand D; Parkhill J; Peacock SJ; Köser CU; Huang H
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5232-7. PubMed ID: 27324769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Characteristic of Both Levofloxacin and Moxifloxacin Resistance in
    Zhang X; Chen X; Wang B; Fu L; Huo F; Gao T; Pang Y; Lu Y; Li Q
    Microb Drug Resist; 2022 Mar; 28(3):280-287. PubMed ID: 34981969
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
    Disratthakit A; Prammananan T; Tribuddharat C; Thaipisuttikul I; Doi N; Leechawengwongs M; Chaiprasert A
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5189-97. PubMed ID: 27297489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.
    Niward K; Ängeby K; Chryssanthou E; Paues J; Bruchfeld J; Jureen P; Giske CG; Kahlmeter G; Schön T
    J Antimicrob Chemother; 2016 Feb; 71(2):333-8. PubMed ID: 26538509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].
    Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China.
    Zheng H; He W; Jiao W; Xia H; Sun L; Wang S; Xiao J; Ou X; Zhao Y; Shen A
    BMC Infect Dis; 2021 Apr; 21(1):330. PubMed ID: 33832459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.
    Willby M; Sikes RD; Malik S; Metchock B; Posey JE
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5427-34. PubMed ID: 26100699
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Tudó G; Lopez-Gavin A; Portell-Buj E; Freixes J; Vila J; Roman A; Monté MR; Gonzalez-Martin J
    Microb Drug Resist; 2020 Sep; 26(9):1019-1022. PubMed ID: 32159449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China.
    Zhu C; Zhang Y; Shen Y; Siu GK; Wu W; Qian X; Deng G; Xu Y; Lau R; Fan X; Zhang W; Lu H; Yam WC
    Diagn Microbiol Infect Dis; 2012 Jul; 73(3):260-3. PubMed ID: 22560167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China.
    Chen J; Chen Z; Li Y; Xia W; Chen X; Chen T; Zhou L; Xu B; Xu S
    Braz J Infect Dis; 2012; 16(2):136-41. PubMed ID: 22552454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.
    Che Y; Bo D; Lin X; Chen T; He T; Lin Y
    BMC Infect Dis; 2021 Jun; 21(1):605. PubMed ID: 34171989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco.
    Chaoui I; Oudghiri A; El Mzibri M
    J Glob Antimicrob Resist; 2018 Mar; 12():171-174. PubMed ID: 29033301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
    Nosova EY; Bukatina AA; Isaeva YD; Makarova MV; Galkina KY; Moroz AM
    J Med Microbiol; 2013 Jan; 62(Pt 1):108-113. PubMed ID: 23019190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Diagnostic Performance of MeltPro and Next-Generation Sequencing in Determining Fluoroquinolone Resistance in Multidrug-Resistant Tuberculosis Isolates.
    Hu Y; Chi Y; Feng X; Yu F; Li H; Shang Y; Pan J; Pang Y
    J Mol Diagn; 2023 Jun; 25(6):342-351. PubMed ID: 37208048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to anti-tuberculosis drugs.
    Imperiale BR; Zumárraga MJ; Di Giulio AB; Cataldi AA; Morcillo NS
    Int J Tuberc Lung Dis; 2013 Aug; 17(8):1088-93. PubMed ID: 23827034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19.
    Tahseen S; Khanzada FM; Rizvi AH; Qadir M; Ghazal A; Baloch AQ; Mustafa T
    PLoS One; 2020; 15(9):e0239328. PubMed ID: 32966321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.